Eterna Therapeutics
ERNA
9 hedge funds and large institutions have $4.94M invested in Eterna Therapeutics in 2018 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, reducing their positions, and closing their positions.
13% more funds holding
Funds holding: 8 → 9 (+1)
2% more capital invested
Capital invested by funds: $4.82M → $4.94M (+$117K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$144K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCPG
Kavar Capital Partners Group
Leawood,
Kansas
|
-$4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BA
1
Bard Associates
Chicago,
Illinois
| $1.33M | – | – | – |
|
|
NSIM
2
North Star Investment Management
Chicago,
Illinois
| $1.32M | – | – | – |
|
|
AIC
3
AWM Investment Company
New York
| $1.27M | – | – | – |
|
|
EAM
4
Eagle Asset Management
St Petersburg,
Florida
| $320K | – | – | – |
|
5
Renaissance Technologies
New York
| $215K | – | – | – |
|
|
6
Citadel Advisors
Miami,
Florida
| $110K | +$144K | +2 | New |
|
7
Vanguard Group
Malvern,
Pennsylvania
| $95K | – | – | – |
|
8
Geode Capital Management
Boston,
Massachusetts
| $94K | – | – | – |
|
|
CA
9
Callahan Advisors
Houston,
Texas
| $84K | – | – | – |
|
10
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $67K | – | – | – |
|
11
UBS Group
Zurich,
Switzerland
| $24K | – | – | – |
|
12
BlackRock
New York
| $13K | – | – | – |
|
13
Barclays
London,
United Kingdom
| $1K | – | – | – |
|
|
LTFS
14
Ladenburg Thalmann Financial Services
Miami,
Florida
| $1K | – | – | – |
|
|
KCPG
15
Kavar Capital Partners Group
Leawood,
Kansas
| – | -$4K | – | – |
|
ERNA Hedge Fund Activity: Q3 2018 in Review
9 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Eterna Therapeutics (ERNA) for Q3 2018, worth a combined $4.94M — up 2.4% from $4.82M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new ERNA positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $144K. The largest seller was Kavar Capital Partners Group, cutting an estimated $4K.
- 9 institutional investors held Eterna Therapeutics (ERNA) as of Q3 2018, up from 8 in Q2 2018.
- Funds reported $4.94M of Eterna Therapeutics stock for Q3 2018, up 2.4% quarter-over-quarter.
- 1 fund opened new Eterna Therapeutics positions in Q3 2018 and 0 closed out, a net change of +1 holder.
- The largest Eterna Therapeutics buyer in Q3 2018 was Citadel Advisors, an estimated $144K added.
- The largest Eterna Therapeutics seller in Q3 2018 was Kavar Capital Partners Group, an estimated $4K sold.
Based on aggregated 13F filings for Q3 2018.